Enanta Pharmaceuticals to Participate in Investor Conferences in September

Rhea-AI Summary

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announces that Jay R. Luly, Ph.D., President and CEO, will participate in two virtual investor conferences in September 2021. These include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Baird 2021 Virtual Global Healthcare Conference on September 14 at 12:15 p.m. ET. Webcasts will be available on Enanta's website. The company focuses on discovering small molecule drugs for viral infections and liver diseases, leveraging royalties from hepatitis C products developed with AbbVie.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investor conferences being webcast in September:

• H.C. Wainwright 23rd Annual Global Investment Conference: One-on-One Meetings on September 13, 2021, with a Corporate Presentation available to view beginning September 13, 2021
• Baird 2021 Virtual Global Healthcare Conference: One-on-One Meetings and a Fireside Chat at 12:15 p.m. ET on September 14, 2021

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 30 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005001/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What investor conferences is Enanta Pharmaceuticals participating in September 2021?

Enanta Pharmaceuticals is participating in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Baird 2021 Virtual Global Healthcare Conference on September 14, 2021.

Who is representing Enanta Pharmaceuticals at the investor conferences?

Jay R. Luly, Ph.D., President and Chief Executive Officer, will represent Enanta Pharmaceuticals at the investor conferences.

How can I watch the Enanta Pharmaceuticals investor conference presentations?

You can watch the Enanta Pharmaceuticals investor conference presentations via live webcast by visiting the 'Events and Presentations' section on their website at www.enanta.com.

What is the focus of Enanta Pharmaceuticals' research and development?

Enanta Pharmaceuticals focuses on discovering small molecule drugs for viral infections and liver diseases, including targets like RSV, HBV, NASH, and COVID-19.

How is Enanta Pharmaceuticals funded?

Enanta Pharmaceuticals is funded through royalties from hepatitis C virus products developed in collaboration with AbbVie.